Wang Chen, Qi Weiran, Yang Ting, Jiao Lirui, Chen Qiushi, Huang Ke, Yu Fengyun, Geldsetzer Pascal, Bärnighausen Till, Chen Simiao
School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
National Clinical Research Center for Respiratory Diseases, Beijing, China.
EClinicalMedicine. 2024 Jul 16;74:102597. doi: 10.1016/j.eclinm.2024.102597. eCollection 2024 Aug.
Understanding the chronic obstructive pulmonary disease (COPD) care cascade is crucial for identifying where and when to intervene to improve COPD outcomes. We aimed to determine the proportion of patients with COPD seeking care in China's health system who are lost at each stage of the COPD care cascade and how the patterns of loss vary across geographical regions and population groups.
From November 3, 2018, to April 22, 2021, we used individual-level patient data from the national Chinese 'Happy Breathing' Programme, which aims to identify patients with COPD and provide appropriate care. COPD was defined as a post-bronchodilator ratio of forced expiratory volume in 1 s to forced vital capacity (FEV1/FVC) <0.70. We calculated the proportions of individuals who, at enrolment into the 'Happy Breathing' Programme, (i) had ever undergone a pulmonary function test, (ii) had been diagnosed with COPD in the past, (iii) were currently on treatment for COPD, and (iv) had achieved control of their COPD. We examined the association between reaching each stage of the care cascade and individual patient characteristics as well as regional-level economic development and available resources in the health system using multilevel regression.
Among the 29,201 patients with COPD in the 'Happy Breathing' Programme, 41.0% (95% confidence interval [CI]: 40.4-41.6%) had ever been tested for COPD, 17.6% (95% CI: 17.1-18.0%) had previously been diagnosed with COPD, 8.5% (95% CI: 8.2-8.8%) were currently on treatment for COPD, 4.6% (95% CI: 4.3-4.8%) of patients had mild or no exacerbations in the prior year, and 3.9% (95% CI: 3.7-4.2%) of patients had suffered no exacerbations in the prior year. On average, patients living in the cities of Beijing, Wuhan, and Yinchuan had progressed further along the COPD care cascade than patients living in Daqing and Luoyang. Using multilevel regression, we found that young age, rural residence, and low regional per-capita GDP were significantly associated with larger losses at each stage of the COPD care cascade.
Substantial proportions of patients with COPD are lost at each stage of the COPD care cascade in the Chinese health system. The largest losses occur during the initial stages of the cascade, when diagnosis first occurs. New policies and interventions are required to boost COPD care, especially screening and diagnosis, in the Chinese health system to reduce this large disease burden.
This work was supported by Major Programme of National Natural Science Foundation of China (82090011), CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-1-049), and Horizon Europe (HORIZON-MSCA-2021-SE-01; project number 101086139-PoPMeD-SuSDeV). TB was supported by the Alexander von Humboldt Foundation through the Alexander von Humboldt professorship award.
了解慢性阻塞性肺疾病(COPD)护理流程对于确定在何处以及何时进行干预以改善COPD治疗效果至关重要。我们旨在确定在中国卫生系统中寻求治疗的COPD患者在COPD护理流程各阶段流失的比例,以及流失模式在不同地理区域和人群中的差异。
从2018年11月3日至2021年4月22日,我们使用了中国全国性“快乐呼吸”项目的个体层面患者数据,该项目旨在识别COPD患者并提供适当护理。COPD被定义为支气管扩张剂使用后1秒用力呼气容积与用力肺活量的比值(FEV1/FVC)<0.70。我们计算了在加入“快乐呼吸”项目时,(i)曾进行过肺功能测试、(ii)过去曾被诊断为COPD、(iii)目前正在接受COPD治疗、以及(iv)COPD已得到控制的个体比例。我们使用多水平回归分析了达到护理流程各阶段与个体患者特征以及地区层面经济发展和卫生系统可用资源之间的关联。
在“快乐呼吸”项目的29201例COPD患者中,41.0%(95%置信区间[CI]:40.4 - 41.6%)曾接受过COPD检测,17.6%(95%CI:17.1 - 18.0%)过去曾被诊断为COPD,8.5%(95%CI:8.2 - 8.8%)目前正在接受COPD治疗,4.6%(95%CI:4.3 - 4.8%)的患者上一年轻度发作或未发作,3.9%(95%CI:3.7 - 4.2%)的患者上一年未发作。平均而言,居住在北京、武汉和银川市的患者在COPD护理流程中的进展比居住在大庆和洛阳的患者更大。使用多水平回归分析,我们发现年轻、农村居住以及地区人均GDP较低与COPD护理流程各阶段的更大流失显著相关。
在中国卫生系统中,相当比例的COPD患者在COPD护理流程的各阶段流失。最大的流失发生在流程的初始阶段,即首次诊断时。需要新的政策和干预措施来加强中国卫生系统中的COPD护理,特别是筛查和诊断,以减轻这一巨大的疾病负担。
本研究得到了中国国家自然科学基金重大项目(82090011)、中国医学科学院医学创新基金(CIFMS)(2021 - I2M - 1 - 049)以及欧洲地平线计划(HORIZON - MSCA - 2021 - SE - 01;项目编号101086139 - PoPMeD - SuSDeV)的支持。TB得到了亚历山大·冯·洪堡基金会通过亚历山大·冯·洪堡教授奖提供的支持。